Mon, Sep 15, 2014, 12:43 AM EDT - U.S. Markets open in 8 hrs 47 mins

Recent

% | $
Quotes you view appear here for quick access.

Santarus, Inc. (SNTS) Message Board

macs7972 2 posts  |  Last Activity: Aug 19, 2014 9:17 PM Member since: Dec 7, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Pen

    by siamesekitty711 Aug 14, 2014 7:17 PM
    macs7972 macs7972 Aug 19, 2014 9:17 PM Flag

    They started the CTH-105 study in July and expect results by the end of Sept. The study is a major catalyst for the company as its the first time their testing APL-130277 in Parkinson patients. The study is meant to find the appropriate dose to be used in their phase 3 study which commences in Q4. They are well financed and just recently raised $ at .65 per share. The company has a clear plan in place to file their NDA in 2016 and then sell the company. Jason Napadano calls this one of his best ideas. Michael J Fox foundation just awarded the company with its second grant and called APL-130277 one of the top ten neurology projects in 2012. I've been loading up over the past few months. I'm gonna sit on this one just like we did with Santarus. Good luck

  • Reply to

    Pen

    by siamesekitty711 Aug 14, 2014 7:17 PM
    macs7972 macs7972 Aug 15, 2014 2:24 PM Flag

    hi kitty, in case you're looking for a good spec play check out CYNAF. Huge upside with low risk. Jason Napadano has a PT of 2.25 and the stock is currently trading at .54.

SNTS
31.960.00(0.00%)Dec 31 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
21Vianet Group, Inc.
NasdaqGSFri, Sep 12, 2014 4:00 PM EDT